Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL 9 study of once-weekly somapacitan in children with growth disorders
NL-OMON60873Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of somapacitan in Small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome and 1 more (4 cohorts), sponsored by Novo Nordisk. Primary endpoint: Number of adverse events. Started Jun 2023; status: completed.
02
Drugs
somapacitan
03
Conditions
Small for gestational age (SGA)Turner syndrome (TS)Noonan syndromeIdiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NL-OMON60873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60873.